Why Intercept Pharmaceuticals Inc. Shares More Than Quadrupled
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Intercept Pharmaceuticals , a clinical-stage biopharmaceutical company focused on developing therapies to treat chronic liver disease, exploded higher by as much as 320% (that's not a misprint) today following a clinical update on its phase 2b Flint trial involving obeticholic acid (OCA) as a treatment for nonalcoholic steathohepatitis (NASH), a disease characterized by fat accumulation in the liver which can lead to cirrhosis, the need for a transplant, or death.
So what: According to Intercept's press release, the data safety monitoring board has recommended the Flint trial be stopped early based on OCA meeting its primary endpoint and highly statistically significant improvement in liver histology. The DSMB reviewed liver biopsy data from roughly half of all trial patients and noted that the primary endpoint - a decrease in the NAFLD Activity Score of at least two points with no worsening of fibrosis - was met.
Now what: In my 15 years of investing, I can recall but a handful of instances where I've seen a non-micro-cap or small-cap company explode higher by 320% in a single session - and certainly none of them moved higher by $230 per share! There are obviously huge implications here for OCA given that an estimates 12% of the U.S. population has NASH and some 6 million people in the U.S. are projected to have advanced liver fibrosis or cirrhosis, which is where OCA could be of incredible benefit. Then again, I am a realist, and a $200-plus move higher better come with absolutely utopian clinical data and execution from here on out or it will be clobbered. As much as today's move is exciting and reminds investors of the potential of the biotech sector, I'm sticking to the sidelines.
Can this top stock follow in Intercept's footsteps in 2014?
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.
The article Why Intercept Pharmaceuticals Inc. Shares More Than Quadrupled originally appeared on Fool.com.Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.